| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-03-22 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.850 | -1.020 | -0.1700 | ||||
| REV | 0 |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Vincerx Pharma (NASDAQ: VINC) through any online brokerage.
Other companies in Vincerx Pharma’s space includes: Alzamend Neuro (NASDAQ:ALZN), 89bio (NASDAQ:ETNB), Adverum Biotechnologies (NASDAQ:ADVM), OncoCyte (NASDAQ:OCX) and Celcuity (NASDAQ:CELC).
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by HC Wainwright & Co. on January 14, 2022. The analyst firm set a price target for 25.00 expecting VINC to rise to within 12 months (a possible 269.28% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Vincerx Pharma (NASDAQ: VINC) is $6.77 last updated Today at 9:00:02 PM.
There are no upcoming dividends for Vincerx Pharma.
Vincerx Pharma’s $Q4 earnings are confirmed for after-market on March 22, 2022.
There is no upcoming split for Vincerx Pharma.
Vincerx Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.